Subscribe

GNI Group Ltd. (2160.T)

JPY2,602.00 +22.00 (+0.85%)
JP JPX Healthcare Biotechnology
Address Nihonbashi-Honcho YS Building 103-0023
Tokyo, JP
CEO Ying Luo
Website gnipharma.com
IPO 2007-08-31
ISIN JP3386370005

Explore sections of this company profile

Description

GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY2,602.00 +22.00 (+0.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.24
Float Shares
53.99M
Free Float %
97.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+9.58% +9.55% +4.31% +32.87% +30.02% +42.79% +31.54% +196.73% +77.62% +268.80% +1,040.70%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2,602.00
DCF (Unlevered) 135.78 -94.8%
DCF (Levered) 40.61 -98.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.93
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +13.7% ★ Q1'26: -32.8% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -497.5% Q1'26: +367.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -30.5% Q1'26: -48.9% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -8.6% Q1'26: +41.8% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -6.4% ★
  • ✗
    Share dilution Biotechnology: -3.4%
    +1.1% ★ Q1'26: +11.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -4.59× Q1'26: 0.90× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.27) × ERP
WACC = 97% × Ke + 3% × Kd (32.6%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 135.83 Current price: 2,602.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2017
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
2 Rev. Ana.
2 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
2.65B
est: 2.91B (-8.9%)
12.69B
est: 12.83B (-1.1%)
17.42B
est: 16.41B (+6.2%)
26.01B
est: 23.65B (+10.0%)
23.61B
est: 34.83B (-32.2%)
26.84B
est: 27.95B (-4.0%)
29.67B
29.05B – 30.28B
+6.2% YoY
39.50B
35.20B – 42.21B
+33.1% YoY
58.66B
57.57B – 59.76B
+48.5% YoY
66.27B
61.48B – 69.50B
+13.0% YoY
73.93B
68.58B – 77.54B
+11.6% YoY
EBITDA
234.38M
est: 682.70M (-65.7%)
1.50B
est: 3.01B (-50.3%)
1.76B
est: 3.85B (-54.4%)
5.19B
est: 1.86B (+179.0%)
436.69M
est: 2.74B (-84.1%)
-1.17B
est: 2.20B (-153.2%)
2.33B
2.28B – 2.38B
+6.2% YoY
3.11B
2.77B – 3.32B
+33.1% YoY
4.61B
4.53B – 4.70B
+48.5% YoY
5.21B
4.83B – 5.47B
+13.0% YoY
5.81B
5.39B – 6.10B
+11.6% YoY
EBIT
144.77M
est: 590.32M (-75.5%)
1.12B
est: 2.61B (-57.2%)
1.23B
est: 3.33B (-63.0%)
4.58B
est: 1.07B (+329.1%)
-546.55M
est: 1.57B (-134.8%)
-2.31B
est: 1.26B (-282.9%)
1.34B
1.31B – 1.37B
+6.2% YoY
1.78B
1.59B – 1.91B
+33.1% YoY
2.65B
2.60B – 2.70B
+48.5% YoY
2.99B
2.77B – 3.14B
+13.0% YoY
3.34B
3.10B – 3.50B
+11.6% YoY
Net Income
-175.21M
est: 225.00M (-177.9%)
1.07B
est: 1.62B (-34.2%)
388.83M
est: 1.19B (-67.4%)
8.09B
est: 6.77B (+19.6%)
1.10B
est: 9.38B (-88.3%)
-4.41B
est: 3.49B (-226.3%)
2.61B
2.41B – 2.80B
-25.4% YoY
4.25B
1.97B – 6.00B
+62.8% YoY
6.56B
5.14B – 7.97B
+54.5% YoY
7.50B
6.80B – 7.98B
+14.4% YoY
8.45B
7.65B – 8.98B
+12.6% YoY
SGA
1.74B
est: 1.77B (-1.6%)
7.96B
est: 7.81B (+1.9%)
10.97B
est: 9.98B (+9.8%)
15.29B
est: 15.23B (+0.4%)
15.77B
est: 22.44B (-29.7%)
19.00B
est: 18.00B (+5.6%)
19.11B
18.71B – 19.50B
+6.2% YoY
25.44B
22.67B – 27.19B
+33.1% YoY
37.78B
37.08B – 38.49B
+48.5% YoY
42.68B
39.60B – 44.77B
+13.0% YoY
47.62B
44.17B – 49.94B
+11.6% YoY
EPS
-4.66
est: 4.33 (-207.5%)
22.72
est: 31.21 (-27.2%)
8.19
est: 23.00 (-64.4%)
169.50
est: 138.16 (+22.7%)
21.96
est: 181.65 (-87.9%)
-84.08
est: 66.59 (-226.3%)
49.70
46.00 – 53.40
-25.4% YoY
79.97
37.50 – 114.40
+60.9% YoY
125.00
98.02 – 151.98
+56.3% YoY
143.00
129.55 – 152.08
+14.4% YoY
161.00
145.86 – 171.22
+12.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 C 2/5 2/5 1/5 1/5 3/5 1/5 3/5
2026-05-07 C 2/5 2/5 1/5 1/5 3/5 1/5 3/5
2026-05-01 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-30 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-28 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-27 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-24 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-23 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-22 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-1.83B
OE per share TTM
-36.13
Owner's Yield
-1.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 45 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI Japan Small Cap UCITS ETF IDJP.L 0.06% 355.7K 0.58%
2 iShares MSCI Japan Small-Cap ETF SCJ 0.06% 156.8K 0.50%
3 State Street SPDR S&P International Small Cap ETF GWX 0.04% 311.6K 0.40%
4 iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ 0.02% 56.4K 0.83%
5 iShares MSCI EAFE Small-Cap ETF SCZ 0.02% 3.39M 0.40%
6 iShares Core MSCI Japan IMI UCITS ETF IJPA.L 0.02% 1.33M 0.12%
7 iShares Core MSCI Japan IMI UCITS ETF SJPD.AS 0.02% 10.6K 0.12%
8 iShares Core MSCI Japan IMI UCITS ETF SJPE.AS 0.02% 22.2K 0.17%
9 iShares Core MSCI Pacific ETF IPAC 0.01% 293.2K 0.09%
10 iShares MSCI World Small-Cap ETF WSML 0.01% 72.5K 0.30%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-2.66M
Shares Outstanding
55.69M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ying Luo Chief Executive Officer, President, Representative Executive Officer & Chair 71M —
Kan-ichiro Suzuki Vice President & Executive Officer — —
Kazuhiro Kawauchi Executive Officer & Chief Business Development Officer — —
Kosuke Tashiro Co-Founder — —
Ryosuke Matsui Executive Officer, VP, COO, CFO & Director — male
Stephen Charnock-Jones Co-Founder — —
Takuya Kaneko Executive Officer, CSO, GM of Administration Div, Head of Grp Alliance Prom Office — male
Cristin Print Co-Founder — —
Zhang Ping Executive Officer & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology